Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

BACKGROUND: Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell subsets are differentially repopulated after...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Mogeda, Carla, van Lierop, Zoë Y. G. J., van der Pol, Susanne M. A., Coenen, Loet, Hogenboom, Laura, Kamermans, Alwin, Rodriguez, Ernesto, van Horssen, Jack, van Kempen, Zoé L. E., Uitdehaag, Bernard M. J., Teunissen, Charlotte E., Witte, Maarten E., Killestein, Joep, de Vries, Helga E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521424/
https://www.ncbi.nlm.nih.gov/pubmed/37752582
http://dx.doi.org/10.1186/s12974-023-02900-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521424/
https://www.ncbi.nlm.nih.gov/pubmed/37752582
http://dx.doi.org/10.1186/s12974-023-02900-z

Ejemplares similares